TY - JOUR
T1 - Intestinal Transplantation With Alemtuzumab (Campath-1H) Induction for Adult Patients
AU - Nishida, S.
AU - Levi, D. M.
AU - Moon, J. I.
AU - Madariaga, J. R.
AU - Kato, T.
AU - Selvaggi, G.
AU - Tryphonopoulos, Panagiotis
AU - DeFaria, W.
AU - Santiago, S.
AU - Gaynor, J.
AU - Weppler, D.
AU - Martinez, E.
AU - Ruiz, P.
AU - Tzakis, A. G.
PY - 2006/7/1
Y1 - 2006/7/1
N2 - Background: Alemtuzumab (Campath-1H [C1H]) is a humanized monoclonal antibody directed against the CD 52 antigen that is present on the surface of T cells, B cells, natural killer cells and monocytes. We studied its application in intestinal transplantation. Methods: This is a retrospective review of adult patients who underwent intestinal transplantation between December 1994 and May 2005. Group 1: non-C1H group (n = 39); group 2: C1H group (n = 37). C1H was administered as an induction immunosuppression in four doses (0.3 mg/kg), or in two doses (30 mg/kg). Tacrolimus levels were maintained at low level (5-10 ng/dL). No maintenance steroids were given. Results: One-year survival of group 1 and group 2 patients were 57% and 70%, respectively. This difference is not statistically significant. Of 37 patients in group 2, 21 are alive. The incidence of rejection was lower in group 2 (P < .005). Average current tacrolimus level is 6.97 ± 3.98 ng/dL. Seventeen patients (81%) are steroid free, and 15 (71%) are maintained solely on tacrolimus. There was no graft versus host disease in group 2. Conclusions: Our preliminary data suggest that C1H can provide effective immunosuppression for intestinal transplantation. Incidence of rejection was less with this regimen using low maintenance tacrolimus and minimal steroids.
AB - Background: Alemtuzumab (Campath-1H [C1H]) is a humanized monoclonal antibody directed against the CD 52 antigen that is present on the surface of T cells, B cells, natural killer cells and monocytes. We studied its application in intestinal transplantation. Methods: This is a retrospective review of adult patients who underwent intestinal transplantation between December 1994 and May 2005. Group 1: non-C1H group (n = 39); group 2: C1H group (n = 37). C1H was administered as an induction immunosuppression in four doses (0.3 mg/kg), or in two doses (30 mg/kg). Tacrolimus levels were maintained at low level (5-10 ng/dL). No maintenance steroids were given. Results: One-year survival of group 1 and group 2 patients were 57% and 70%, respectively. This difference is not statistically significant. Of 37 patients in group 2, 21 are alive. The incidence of rejection was lower in group 2 (P < .005). Average current tacrolimus level is 6.97 ± 3.98 ng/dL. Seventeen patients (81%) are steroid free, and 15 (71%) are maintained solely on tacrolimus. There was no graft versus host disease in group 2. Conclusions: Our preliminary data suggest that C1H can provide effective immunosuppression for intestinal transplantation. Incidence of rejection was less with this regimen using low maintenance tacrolimus and minimal steroids.
UR - http://www.scopus.com/inward/record.url?scp=33746867891&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746867891&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2006.05.057
DO - 10.1016/j.transproceed.2006.05.057
M3 - Article
C2 - 16908270
AN - SCOPUS:33746867891
VL - 38
SP - 1747
EP - 1749
JO - Transplantation Proceedings
JF - Transplantation Proceedings
SN - 0041-1345
IS - 6
ER -